Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Your treatment will depend on whether your sleep apnea is mild, moderate or severe. Your doctor can help you choose the best treatment for you. The most common treatment for sleep apnea is CPAP or ...

On Monday, Citi analysts increased the price target for ResMed stock to AUD45.00 from AUD44.00, maintaining a Buy rating. This adjustment follows ResMed’s third-quarter results, which aligned with ...

On Monday, Citi analysts adjusted their outlook on ResMed stock, raising the price target to AUD45 from AUD44 while maintaining a Buy rating. This adjustment follows ResMed’s in-line third-quarter ...

On Monday, Citi analysts increased the price ... ResMed anticipates increased promotional activity from its sponsors in the second half of calendar year 2025. The future impact of GLP-1 medications ...